In addition, cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors, small molecules that represent the current standard therapy, in association with hormone therapy, for the adjuvant treatment of high-risk, hormone-positive BC, may prolong cancer cell dormancy by preventing the transition from G1 to S phase [167]. Here, CDK4 is linked to breast cancer.